Literature DB >> 11831723

The acidic amino-terminal region of varicella-zoster virus open reading frame 4 protein is required for transactivation and can functionally replace the corresponding region of herpes simplex virus ICP27.

M Moriuchi1, H Moriuchi, S Debrus, J Piette, J I Cohen.   

Abstract

Both varicella-zoster virus open reading frame 4 (ORF4) protein and its herpes simplex virus type 1 homolog ICP27 have highly acidic amino-terminal regions and cysteine-rich carboxy-terminal regions. To investigate the functional domains of these proteins, mutants were constructed and their transregulatory functions were tested in transient expression assays using two reporter plasmids, pTK-CAT-SV40A and pTK-CAT-synA, containing the same promoter sequences but different mRNA processing signals. ORF4 transactivates both pTK-CAT-SV40A and pTK-CAT-synA, while ICP27 transrepresses pTK-CAT-SV40A and transactivates pTK-CAT-synA. Deletion of the ORF4 amino-terminal region abolished most of the transactivating activity for pTK-CAT-synA but retained most of the transactivating activity for pTK-CAT-SV40A. Construction of chimeric ORF4-ICP27 molecules indicated that the ORF4 amino-terminal region was able to replace the corresponding region of ICP27 which is required for both transrepression of pTK-CAT-SV40A and transactivation of pTK-CAT-synA. Similarly, the ICP27 amino-terminal region was able to partially replace the corresponding region of ORF4 which is required for transactivation of pTK-CAT-synA Thus, while ORF4 and ICP27 have different properties in transient expression assays, the amino-terminal regions of ORF4 and ICP27 are functionally homologous to each other and are important in regulating gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 11831723     DOI: 10.1006/viro.1995.1164

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency.

Authors:  Jeffrey I Cohen; Tammy Krogmann; Jeffrey P Ross; Lesley Pesnicak; Elena A Prikhod'ko
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Absence or overexpression of the Varicella-Zoster Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces VZV latency in a rodent model.

Authors:  Jeffrey I Cohen; Tammy Krogmann; Lesley Pesnicak; Mir A Ali
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

3.  Varicella-zoster virus open reading frame 4 encodes an immediate-early protein with posttranscriptional regulatory properties.

Authors:  P Defechereux; S Debrus; L Baudoux; B Rentier; J Piette
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  The simian varicella virus ORF A is expressed in infected cells but is non-essential for replication in cell culture.

Authors:  Wayne L Gray
Journal:  Arch Virol       Date:  2012-06-08       Impact factor: 2.574

Review 5.  Comparative Analysis of the Simian Varicella Virus and Varicella Zoster Virus Genomes.

Authors:  Wayne L Gray
Journal:  Viruses       Date:  2022-04-19       Impact factor: 5.818

6.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

7.  Requirement of varicella-zoster virus immediate-early 4 protein for viral replication.

Authors:  Bunji Sato; Marvin Sommer; Hideki Ito; Ann M Arvin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  KSHV ORF57, a protein of many faces.

Authors:  Vladimir Majerciak; Zhi-Ming Zheng
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

9.  Varicella-zoster virus IE4 protein interacts with SR proteins and exports mRNAs through the TAP/NXF1 pathway.

Authors:  Isabelle Ote; Marielle Lebrun; Patricia Vandevenne; Sébastien Bontems; Cahora Medina-Palazon; Evelyne Manet; Jacques Piette; Catherine Sadzot-Delvaux
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.